Skip to content
Center for Reproductive Rights
Center for Reproductive Rights

Primary Menu

  • About
    • Overview
    • The Center’s Impact
    • Center Leadership & Staff
    • Annual Reports
    • Corporate Engagement
    • Diversity, Equity and Inclusion
    • Careers
    • Contact Us
  • Work
    • Overview
    • Litigation
    • Legal Policy and Advocacy
    • Resources & Research
    • Recent Case Highlights
    • Landmark Cases
    • Cases Archive
    • World’s Abortion Laws Map
    • After Roe Fell: Abortion Laws by State
  • Issues
    • Overview
    • Abortion
    • Adolescent Sexual and Reproductive Health and Rights
    • Assisted Reproduction
    • Contraception
    • Humanitarian Settings
    • Maternal Health
    • COVID-19
  • Regions
    • Overview
    • Global Advocacy
    • Africa
    • Asia
    • Europe
    • Latin America and the Caribbean
    • United States
  • News
    • Latest News
    • Stories
    • Events
    • Center in the Spotlight
    • Press Releases
    • Statements
    • Press Room
    • Newsletters
  • Resources
    • Resources & Research
    • U.S. Abortion Rights: Resources
    • Maps
    • World Abortion Laws Map
    • After Roe Fell: Abortion Laws by State
    • Repro Red Flags: Agency Watch
  • Act
    • Overview
    • Give
    • Act
    • Learn
  • Donate
    • Become a Monthly Donor
    • Make a Donor Advised Fund Gift
    • Leave a Legacy Gift
    • Donate Gifts of Stock
    • Give a Gift in Honor
    • Attend an Event
    • Employee Matching Gifts
    • Mail a Check
  • Twitter
  • Facebook
  • Instagram
  • YouTube
  • LinkedIn
Donate
icon-hamburger icon-magnifying-glass Donate
icon-magnifying-glass-teal

Laws and Regulations Affecting Medical Abortion

Center for Reproductive Rights - Center for Reproductive Rights - search logo
search Close Close icon
Center for Reproductive Rights -
Menu Close Menu Close icon
Donate

Primary Menu

  • About
    • Overview
    • The Center’s Impact
    • Center Leadership & Staff
    • Annual Reports
    • Corporate Engagement
    • Diversity, Equity and Inclusion
    • Careers
    • Contact Us
  • Work
    • Overview
    • Litigation
    • Legal Policy and Advocacy
    • Resources & Research
    • Recent Case Highlights
    • Landmark Cases
    • Cases Archive
    • World’s Abortion Laws Map
    • After Roe Fell: Abortion Laws by State
  • Issues
    • Overview
    • Abortion
    • Adolescent Sexual and Reproductive Health and Rights
    • Assisted Reproduction
    • Contraception
    • Humanitarian Settings
    • Maternal Health
    • COVID-19
  • Regions
    • Overview
    • Global Advocacy
    • Africa
    • Asia
    • Europe
    • Latin America and the Caribbean
    • United States
  • News
    • Latest News
    • Stories
    • Events
    • Center in the Spotlight
    • Press Releases
    • Statements
    • Press Room
    • Newsletters
  • Resources
    • Resources & Research
    • U.S. Abortion Rights: Resources
    • Maps
    • World Abortion Laws Map
    • After Roe Fell: Abortion Laws by State
    • Repro Red Flags: Agency Watch
  • Act
    • Overview
    • Give
    • Act
    • Learn
  • Donate
    • Become a Monthly Donor
    • Make a Donor Advised Fund Gift
    • Leave a Legacy Gift
    • Donate Gifts of Stock
    • Give a Gift in Honor
    • Attend an Event
    • Employee Matching Gifts
    • Mail a Check
  • Twitter
  • Facebook
  • Instagram
  • YouTube
  • LinkedIn

Related Content

Issues:

Abortion

Regions:

United States

Work:

Reporting on Rights

Type:

Publications, Fact Sheets

Follow the Center

Donate Now

Join Now

07.01.2003

Reporting on Rights Abortion United States Publications

Laws and Regulations Affecting Medical Abortion

Justin Goldberg

Share

  • facebook
  • Twitter
  • linkedin
  • Email id



Medical abortion is a safe and effective non-surgical method of early pregnancy termination. The FDA has approved one drug specifically for use in early abortions.1 Mifepristone (also known as RU 486) is now available under the trade name Mifeprex. This medication has been used successfully by more that half a million women in Europe for over a decade and has recently undergone the rigorous Food and Drug Administration (FDA) approval process.



Abortion is one of the most highly scrutinized, politicized and regulated medical procedures performed today in the United States. The majority of the abortion laws were drafted at a time when medical abortion was not available and pregnancy termination was always achieved by surgical means. Despite the fact that many of these laws do not make sense in the context of medical abortion, they can and will be most likely enforced against providers of medical abortion.



Some states have issued regulations or passed legislation to formally include medical abortion in a legal definition of abortion previously only applied to surgical procedures, while others have tried to further restrict its use. Members of Congress, the Administration, and state lawmakers are also considering further burdensome regulations. All of these restrictions are unnecessary, as anti-abortion state legislatures have already erected a labyrinth of laws restricting all abortions, and the safety of mifepristone is well established. The following examines some of the ways that these existing abortion restrictions apply to medical abortion.



“Physician–Only” Laws



Some non-physician health care providers, such as physician assistants, advanced registered nurses or nurse midwives, currently have the authority to prescribe or dispense a range of drugs under their state laws. However, the majority of states enforce “physician-only” laws that make abortion a crime unless performed by a licensed physician. Thus, non-physicians who provide medical abortion in the 45 jurisdictions with “physician-only” laws risk prosecution and penalties under the law. Some government officials may choose to ignore these laws because they believe they were not intended to apply to medical abortion but prosecutors in anti-choice jurisdictions may well be inclined to take legal action against mid-level providers who prescribe or dispense abortifacients.



Targeted Regulation of Abortion Providers (“TRAP”) Laws



Many states have enacted burdensome laws that single out facilities at which abortions are performed and subject them to regulations that do not apply to other physician offices or outpatient clinics. Targeted regulation of abortion providers, or “TRAP” laws, vary with regard to the burdens imposed, facilities to which they apply, and the type of abortion performed. Some TRAP laws require compliance with relatively minimal licensing provisions while others contain detailed and sometimes confusing and expensive structural, staffing, patient testing and other requirements. TRAP laws pose a deterrent to the use of medical abortion, as onerous requirements may limit the number of providers and/or clinics willing to offer medical abortion. In general, TRAP laws do apply to medical as well as surgical abortions.



Forced Parental Involvement and Mandatory Delay Laws



As a general matter, state laws that require parental consent or notice before an abortion may be performed (forced parental involvement laws) and state laws that require a waiting period after a woman receives certain state-scripted information (mandatory delay and biased counseling laws) apply to medical abortion just as they do to surgical abortion.



More than half the states enforce some form of forced parental notice or consent law. Some states require that notice to the parents be followed by a waiting period (up to 48 hours). Some states also currently enforce waiting period laws on women of all ages seeking abortions and these laws apply to medical, as well as surgical, abortion. Most often, these waiting periods must occur before the first dose of mifepristone is administered.



Food and Drug Administration Regulations



In approving mifepristone for use as an abortifacient, the FDA enumerated various restrictions on distribution of the drug. The drug must be provided by or under the supervision of a physician who is able to assess the duration of pregnancy accurately and to diagnose ectopic pregnancies. Practitioners prescribing mifepristone must either have the ability to provide surgical intervention in uncommon cases of incomplete abortion or severe bleeding, or have made plans to provide such care through other qualified physicians. While complications are rare, providers must also be able to assure patient access to fully equipped medical facilities.



In addition, FDA guidelines include a protocol ensuring that all patients receive a full explanation of the procedure and are provided with an opportunity to discuss any questions regarding medical abortion. Providers must then obtain the woman’s signature on a patient agreement, which they must sign as well. Physicians prescribing mifepristone must also agree to report any serious complications, including information about any patients for whom mifepristone is not effective, resulting in the need for a surgical abortion. It should be noted, however, that a woman’s signature on a patient agreement does not replace the state law concerning informed consent procedures.2



Other Laws Affecting Medical Abortion



Numerous states have laws that require specific kinds of disposal or examination of fetal tissue after an abortion. These laws are generally impractical or even irrational when applied to medical abortion because the woman usually expels the fetal tissue at home. The health care provider who prescribed the drugs for the medical abortion could, however, face penalties or prosecution unless the tissue is saved and examined.



Most states require abortion providers to report certain information to the state or keep records of certain information for possible state inspection. Many states require a provider to report each abortion that is performed. These reporting requirements apply to medical abortion as well.



New Efforts to Restrict Medical Abortion



New legislation aimed at directly restricting medical abortion has been proposed in at least 12 states. The new legislation includes bills that clarify the definition of abortion to include mifepristone, exclude medical abortion from public funding for low-income women, and go as far as making a felony to prescribe or to dispense mifepristone.



Anti-choice politicians in Congress introduced the “Patient Health and Safety Act” in February 2003 in the House of Representatives. If enacted, the measure would, among other restrictions, severely limit the pool of providers of mifepristone to doctors who currently provide surgical abortions, who are “certified” in ultrasound for dating pregnancy, and who have admitting privileges at an emergency room located within one hour of their office. In attempting to impose further restrictions on mifepristone, anti-choice legislators are challenging the integrity of medical practice as well as the FDA’s decision-making process.



In August 2002 a coalition of anti-choice groups submitted a 92-page petition to the FDA calling for the Commissioner of the FDA to halt all distribution and marketing of the drug. Additionally, President Bush has appointed Dr. David Hager as a member of the Reproductive Health Drugs Advisory Committee of the Food and Drug Administration (FDA), the committee that is responsible for analyzing the safety and effectiveness of drugs used in reproductive health care. Dr. Hager, prior to this appointment, reportedly helped draft the petition requesting the FDA to rescind its approval of mifespristone, which is used to provide safe, early medical abortions. Further restrictions could be eminent as the petition is considered by the panel on which Dr. Hager now sits.



The Center for Reproductive Rights Files First Lawsuit in the Nation Against Ban on Medical Abortions



As a result of the Center for Reproductive Rights’ lawsuit, Michigan reversed its ban on medical abortion in March 2001. A settlement between the Center for Reproductive Rights and the state resolved most of the challenge to Michigan’s mandatory delay for abortion law, which had been modified to prohibit state-mandated abortion literature from describing any procedure that uses a drug that hasn’t been specifically FDA-approved for use in an abortion. Misoprostol, FDA-approved as an ulcer medication and used “off-label,” is necessary to successfully complete an abortion using mifepristone.



After a 1995 Mifepristone clinical trial involving 2,100 women in the U.S.:



  • 96% of the women said they would recommend mifepristone to other women seeking an abortion

  • Over 90% said they’d choose it again if they were to have another abortion

  • More than 3/4 of the women who had already experienced a surgical abortion said that medical abortion was preferable



*Statistics from 1998 Kaiser Report “Will 1999 Be the Year for Mifepristone (RU-486)?”


Notes


1 Oklahoma HB 1038

2 HR 486, sponsored by Vitter. S 251, sponsored by Hutchinson.


Related Posts

Adams & Boyle, P.C. et al v. Slatery, et al: Order

Abortion,United States,Reporting on Rights

MKB Management Corp v. Burdick: Order Adopting Settlement Stipulation

Order from the trial court adopting the settlement stipulation awarding attorney's fees and costs from the state of North Dakota.

Abortion, Anti-Choice Harassment, Legal Restrictions, Maternal Health, Access to Quality Care,United States,In the Courts, Engaging Policymakers, In the States (USA), Reporting on Rights

MKB Management Corp v. Burdick: Eighth Circuit Court Decision

Abortion, Anti-Choice Harassment, Legal Restrictions, Maternal Health, Access to Quality Care,United States,In the Courts, Engaging Policymakers, In the States (USA), Reporting on Rights

Sign up for email updates.

The most up-to-date news on reproductive rights, delivered straight to you.

Footer Menu

  • Careers
  • Privacy Policy
  • Gift Acceptance Policy
  • Contact Us

Center for Reproductive Rights
© (1992-2024)

Use of this site signifies agreement with our disclaimer and privacy policy.

Better Business Bureau Charity Watch Top Rated Center for Reproductive Rights
This site uses necessary, analytics and social media cookies to improve your experience and deliver targeted advertising. Click "Options" or click here to learn more and customize your cookie settings, otherwise please click "Accept" to proceed.
OPTIONSACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThis cookie is installed by Google Analytics. The cookie is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. The cookies store information anonymously and assign a randomly generated number to identify unique visitors.
_gat_UA-6619340-11 minuteNo description
_gid1 dayThis cookie is installed by Google Analytics. The cookie is used to store information of how visitors use a website and helps in creating an analytics report of how the wbsite is doing. The data collected including the number visitors, the source where they have come from, and the pages viisted in an anonymous form.
_parsely_session30 minutesThis cookie is used to track the behavior of a user within the current session.
HotJar: _hjAbsoluteSessionInProgress30 minutesNo description
HotJar: _hjFirstSeen30 minutesNo description
HotJar: _hjid1 yearThis cookie is set by Hotjar. This cookie is set when the customer first lands on a page with the Hotjar script. It is used to persist the random user ID, unique to that site on the browser. This ensures that behavior in subsequent visits to the same site will be attributed to the same user ID.
HotJar: _hjIncludedInPageviewSample2 minutesNo description
HotJar: _hjIncludedInSessionSample2 minutesNo description
HotJar: _hjTLDTestsessionNo description
SSCVER1 year 24 daysThe domain of this cookie is owned by Nielsen. The cookie is used for online advertising by creating user profile based on their preferences.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
CookieDurationDescription
_fbp3 monthsThis cookie is set by Facebook to deliver advertisement when they are on Facebook or a digital platform powered by Facebook advertising after visiting this website.
fr3 monthsThe cookie is set by Facebook to show relevant advertisments to the users and measure and improve the advertisements. The cookie also tracks the behavior of the user across the web on sites that have Facebook pixel or Facebook social plugin.
IDE1 year 24 daysUsed by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
IMRID1 year 24 daysThe domain of this cookie is owned by Nielsen. The cookie is used for storing the start and end of the user session for nielsen statistics. It helps in consumer profiling for online advertising.
personalization_id2 yearsThis cookie is set by twitter.com. It is used integrate the sharing features of this social media. It also stores information about how the user uses the website for tracking and targeting.
TDID1 yearThe cookie is set by CloudFare service to store a unique ID to identify a returning users device which then is used for targeted advertising.
test_cookie15 minutesThis cookie is set by doubleclick.net. The purpose of the cookie is to determine if the user's browser supports cookies.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
CookieDurationDescription
adEdition1 dayNo description
akaas_MSNBC10 daysNo description
cookielawinfo-checkbox-functional1 yearThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-others1 yearNo description
geoEdition1 dayNo description
next-i18next1 yearNo description
SAVE & ACCEPT
Powered by CookieYes Logo
Scroll Up